Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
Status:
RECRUITING
Trial end date:
2027-04-01
Target enrollment:
Participant gender:
Summary
This study will evaluate whether the combination of sacituzumab govitecan (SG) and bevacizumab will result in shrinkage of brain metastases from patients with non-squamous non-small cell lung cancer (NSCLC), with disease progression on chemotherapy and immunotherapy.